Uvéite II : Mises à jour dans le domaine de l’uvéite
Mon statut pour la session
Objectifs d’apprentissage
À la fin de la séance, les participants pourront :
- Acquérir une compréhension globale de la pathophysiologie et des options de traitement pour différents types de maladies inflammatoires oculaires, y compris la pars planite, l’uvéite non infectieuse et la syphilis oculaire.
- Mieux comprendre les différents facteurs qui ont une incidence sur les résultats cliniques et le pronostic à long terme chez les patients ayant une maladie inflammatoire oculaire, incluant l’utilisation d’un traitement immunomodulateur systémique et l’efficacité de différentes modalités de traitement.
Rôles CanMEDS : Expert médical, Collaborateur
Sous sessions
Author Block: Daniel Lamoureux 1, David Wong2, Tina Felfeli2. 1Northern Ontario School of Medicine, 2University of Toronto. Author Disclosure Block: D. Lamoureux: None. D. Wong: None. T. Felfeli: None.Abstract Body: Purpose: The u...
Author Block: 1 Natalie Kozlowski2, Felicia Tai3, Jorge R. Georgakopoulos4, Elizabeth Uleryk, Rafael N. Miranda5, 6. 1Temerty Faculty of Medicine, University of Toronto, 2Division of Ophthalmology, McMaster University, 3University of Toronto, 4E/M Uleryk Consulting, 5Toronto Health Economics and Technology Assessment (THETA)...
Author Block: Raheem Remtulla , Karin M. Oliver. McGill University. Author Disclosure Block: R. Remtulla: None. K.M. Oliver: None.Abstract Body: Purpose: Immune checkpoint inhibitors (ICIs) inhibit the regulators of the immune...
Author Block: Christine E. Ashenhurst 1, Patrick Mitchell2, Michael Y. K. Mak3, Micheal T. Kryshtalskyj2. 1University of Victoria, 2University of Calgary, 3McGill University.Author Disclosure Block: C.E. Ashenhurst: None. P. Mitchell: None. M.Y.K. Mak: None. M.T. Krysht...
Author Block: Daniel Milad , Fares Antaki, Allison Bernstein, Samir Touma, Renaud Duval. Université de Montréal.Author Disclosure Block: D. Milad: None. F. Antaki: Funded grants or clinical trials; Name of for-profit or not-for-profit organization(s); Bayer. Funded grants or clinical trials; Descr...
Author Block: Carol Tadrous , Steven Schendel, Kaivon Vaezi, Kulbir S. Gill, Mahadev Bhalla, Derek Chan, Claudio Perez. University of British Columbia. Author Disclosure Block: C. Tadrous: None. S. Schendel: Any direct financial payments including receipt of honoraria; Name of for-profit or not-for-profit organization(s); Abbvie, Alcon, Glaukos, Labtician, Thea, Bausch and Lomb. Any direct financial payments including receipt o...
Author Block: Tina Felfeli 1, Arshia Eshtiaghi2, Jess Rhee3, Michael Balas2, Felicia Tai4, Laurence A. Rubin5, Nupura K. Bakshi6, Larissa Derzko-Dzulynsky7. 1Department of Ophthalmology and Vision Sciences, University of Toronto; Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto, 2The Temerty Faculty of Medicine, University of Toronto, 3Faculty of Medicine, Schulich School of Medicine and Dentistry, 4Division of Ophthalmology, McMaster University, 5Divisi...
Author Block: Mélanie Hébert 1, Ryan Hendrick2, Keith Perry2, Mohammed Al-Kaabi3, Anna Polosa3, Marie-Josée Aubin3. 1Hôpital Saint-Sacrement, CHU de Québec - Université Laval, 2Université de Montréal, 3Centre universitaire d'ophtalmologie, Hôpital Maisonneuve-Rosemont.Author Disclosure Block: M. Hébert: Funded grants or clinical trials; Name of for-profit or not-for-profit organization(s); Bayer, Fighting Blindness Canada, Vision Health Research...
Author Block: Keith Perry 1, Mélanie Hébert2, Ryan Hendrick1, Mohammed Al Kaabi3, Anna Polosa3 Marie-Josée Aubin3. 1Université de Montréal, 2Hôpital Saint-Sacrement, CHU de Québec - Université Laval, 3Centre universitaire d'ophtalmologie, Hôpital Maisonneuve-Rosemont. Author Disclosure Block: K. Perry: None. M. Hébert: Funded grants or clinical trials; Name of for-profit or not-for-profit organization(s); Bayer, Fighting Bl...